Mycoplasma-associated Stevens-Johnson syndrome in children: Retrospective review of patients managed with or without intravenous immunoglobulin, systemic corticosteroids, or a combination of therapies

Jusleen Ahluwalia, Joy Wan, Diana H. Lee, James Treat, Albert C. Yan

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Administration of intravenous immunoglobulin (IVIG) to patients with Stevens-Johnson syndrome (SJS) has been controversial. The objective of this study was to evaluate the effectiveness of IVIG, systemic corticosteroids, or both in treating Mycoplasma pneumoniae-associated SJS (mpSJS). Retrospective series of 10 pediatric mpSJS cases were stratified into four treatment groups: IVIG alone, IVIG and systemic corticosteroids together, systemic corticosteroids alone, and supportive care. The efficacy of therapy was evaluated on the basis of several proxies of disease severity, including hospital length of stay (LOSt) and number of febrile days (Febt) after initiation of therapy. Patients treated with IVIG alone had a longer LOSt and more Febt, despite different baseline characteristics, than patients treated with supportive therapy. Of patients who received IVIG, 50% were treated with corticosteroids concurrently and had similar characteristics of disease severity but showed a non-statistically significant trend toward shorter LOSt and fewer Febt than those who received IVIG alone. A patient treated with corticosteroids alone had the shortest LOSt in this series. Therefore treatment with IVIG alone was associated with a more severe disease course than supportive therapy, although causality cannot be inferred given possible confounding by indication. When systemic corticosteroids were used alone or in conjunction with IVIG, hospital LOSt and Febt trended lower than with the use of IVIG alone, although disease severity at baseline was similar between those treated with IVIG and corticosteroids concurrently and those treated with IVIG alone. It was thus concluded that treatment with systemic corticosteroids as monotherapy or in combination with IVIG may be preferable to IVIG alone. Further large-scale studies are warranted to evaluate this hypothesis.

Original languageEnglish (US)
Pages (from-to)664-669
Number of pages6
JournalPediatric Dermatology
Volume31
Issue number6
DOIs
StatePublished - Nov 1 2014

Fingerprint

Stevens-Johnson Syndrome
Mycoplasma
Intravenous Immunoglobulins
Adrenal Cortex Hormones
Length of Stay
Therapeutics
Mycoplasma pneumoniae
Proxy
Causality

ASJC Scopus subject areas

  • Dermatology
  • Pediatrics, Perinatology, and Child Health

Cite this

Mycoplasma-associated Stevens-Johnson syndrome in children : Retrospective review of patients managed with or without intravenous immunoglobulin, systemic corticosteroids, or a combination of therapies. / Ahluwalia, Jusleen; Wan, Joy; Lee, Diana H.; Treat, James; Yan, Albert C.

In: Pediatric Dermatology, Vol. 31, No. 6, 01.11.2014, p. 664-669.

Research output: Contribution to journalArticle

@article{f0c0f807c2f34272abc68a29a33565a1,
title = "Mycoplasma-associated Stevens-Johnson syndrome in children: Retrospective review of patients managed with or without intravenous immunoglobulin, systemic corticosteroids, or a combination of therapies",
abstract = "Administration of intravenous immunoglobulin (IVIG) to patients with Stevens-Johnson syndrome (SJS) has been controversial. The objective of this study was to evaluate the effectiveness of IVIG, systemic corticosteroids, or both in treating Mycoplasma pneumoniae-associated SJS (mpSJS). Retrospective series of 10 pediatric mpSJS cases were stratified into four treatment groups: IVIG alone, IVIG and systemic corticosteroids together, systemic corticosteroids alone, and supportive care. The efficacy of therapy was evaluated on the basis of several proxies of disease severity, including hospital length of stay (LOSt) and number of febrile days (Febt) after initiation of therapy. Patients treated with IVIG alone had a longer LOSt and more Febt, despite different baseline characteristics, than patients treated with supportive therapy. Of patients who received IVIG, 50{\%} were treated with corticosteroids concurrently and had similar characteristics of disease severity but showed a non-statistically significant trend toward shorter LOSt and fewer Febt than those who received IVIG alone. A patient treated with corticosteroids alone had the shortest LOSt in this series. Therefore treatment with IVIG alone was associated with a more severe disease course than supportive therapy, although causality cannot be inferred given possible confounding by indication. When systemic corticosteroids were used alone or in conjunction with IVIG, hospital LOSt and Febt trended lower than with the use of IVIG alone, although disease severity at baseline was similar between those treated with IVIG and corticosteroids concurrently and those treated with IVIG alone. It was thus concluded that treatment with systemic corticosteroids as monotherapy or in combination with IVIG may be preferable to IVIG alone. Further large-scale studies are warranted to evaluate this hypothesis.",
author = "Jusleen Ahluwalia and Joy Wan and Lee, {Diana H.} and James Treat and Yan, {Albert C.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1111/pde.12481",
language = "English (US)",
volume = "31",
pages = "664--669",
journal = "Pediatric Dermatology",
issn = "0736-8046",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Mycoplasma-associated Stevens-Johnson syndrome in children

T2 - Retrospective review of patients managed with or without intravenous immunoglobulin, systemic corticosteroids, or a combination of therapies

AU - Ahluwalia, Jusleen

AU - Wan, Joy

AU - Lee, Diana H.

AU - Treat, James

AU - Yan, Albert C.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Administration of intravenous immunoglobulin (IVIG) to patients with Stevens-Johnson syndrome (SJS) has been controversial. The objective of this study was to evaluate the effectiveness of IVIG, systemic corticosteroids, or both in treating Mycoplasma pneumoniae-associated SJS (mpSJS). Retrospective series of 10 pediatric mpSJS cases were stratified into four treatment groups: IVIG alone, IVIG and systemic corticosteroids together, systemic corticosteroids alone, and supportive care. The efficacy of therapy was evaluated on the basis of several proxies of disease severity, including hospital length of stay (LOSt) and number of febrile days (Febt) after initiation of therapy. Patients treated with IVIG alone had a longer LOSt and more Febt, despite different baseline characteristics, than patients treated with supportive therapy. Of patients who received IVIG, 50% were treated with corticosteroids concurrently and had similar characteristics of disease severity but showed a non-statistically significant trend toward shorter LOSt and fewer Febt than those who received IVIG alone. A patient treated with corticosteroids alone had the shortest LOSt in this series. Therefore treatment with IVIG alone was associated with a more severe disease course than supportive therapy, although causality cannot be inferred given possible confounding by indication. When systemic corticosteroids were used alone or in conjunction with IVIG, hospital LOSt and Febt trended lower than with the use of IVIG alone, although disease severity at baseline was similar between those treated with IVIG and corticosteroids concurrently and those treated with IVIG alone. It was thus concluded that treatment with systemic corticosteroids as monotherapy or in combination with IVIG may be preferable to IVIG alone. Further large-scale studies are warranted to evaluate this hypothesis.

AB - Administration of intravenous immunoglobulin (IVIG) to patients with Stevens-Johnson syndrome (SJS) has been controversial. The objective of this study was to evaluate the effectiveness of IVIG, systemic corticosteroids, or both in treating Mycoplasma pneumoniae-associated SJS (mpSJS). Retrospective series of 10 pediatric mpSJS cases were stratified into four treatment groups: IVIG alone, IVIG and systemic corticosteroids together, systemic corticosteroids alone, and supportive care. The efficacy of therapy was evaluated on the basis of several proxies of disease severity, including hospital length of stay (LOSt) and number of febrile days (Febt) after initiation of therapy. Patients treated with IVIG alone had a longer LOSt and more Febt, despite different baseline characteristics, than patients treated with supportive therapy. Of patients who received IVIG, 50% were treated with corticosteroids concurrently and had similar characteristics of disease severity but showed a non-statistically significant trend toward shorter LOSt and fewer Febt than those who received IVIG alone. A patient treated with corticosteroids alone had the shortest LOSt in this series. Therefore treatment with IVIG alone was associated with a more severe disease course than supportive therapy, although causality cannot be inferred given possible confounding by indication. When systemic corticosteroids were used alone or in conjunction with IVIG, hospital LOSt and Febt trended lower than with the use of IVIG alone, although disease severity at baseline was similar between those treated with IVIG and corticosteroids concurrently and those treated with IVIG alone. It was thus concluded that treatment with systemic corticosteroids as monotherapy or in combination with IVIG may be preferable to IVIG alone. Further large-scale studies are warranted to evaluate this hypothesis.

UR - http://www.scopus.com/inward/record.url?scp=84912045083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912045083&partnerID=8YFLogxK

U2 - 10.1111/pde.12481

DO - 10.1111/pde.12481

M3 - Article

C2 - 25424206

AN - SCOPUS:84912045083

VL - 31

SP - 664

EP - 669

JO - Pediatric Dermatology

JF - Pediatric Dermatology

SN - 0736-8046

IS - 6

ER -